Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MeiraGTx Holdings plc
MGTX | US
9.24
USD-0.56
-5.71%
MGTX | US
About MeiraGTx Holdings plc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
9.24
Open
9.62
High
9.80
Low
9.19
MeiraGTx Holdings plc a clinical stage gene therapy company focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases including inherited retinal diseases and large degenerative ocular diseases neurodegenerative diseases and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia X-linked retinitis pigmentosa and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals Inc. for the research development and commercialization of gene therapies for the treatment of inherited retinal disease. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York New York.
View LessMGTX | US
Risk
57.2
Sharpe
1.28
Luna's Score
36/100
Recommendation
Sell
Luna says (MGTX | US)
What's Working
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
75.7%1 month
57.2%3 months
73.0%6 months
62.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
2.27
Price to book
5.92
Debt to equity
1.09
Debt to assets
0.33
Ent. to EBITDA
-3.29
Ent. to rev.
56.82
PEG
-
Other Fundamentals
EBITDA
-155.31M
MarketCap
713.18M
MarketCap(USD)
713.18M
Div. yield
-
Op. margin
-16.28K
Erngs. growth
-
Rev. growth
-92.00
Ret. on equity
-91.51
Short ratio
11.53
Short perc.
3.46
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.76
Range1M
1.76
Range3M
5.23
Volumes: Market Activity
Rel. volume
1.00
Price X volume
7.25M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.29 | - | Cheaper |
| Ent. to Revenue | 56.82 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 5.92 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 73.04 | - | Par |
| Debt to Equity | 1.09 | -1.23 | Expensive |
| Debt to Assets | 0.33 | 0.25 | Expensive |
| Market Cap | 713.18M | - | Emerging |
